Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Mon... (The selling and administrative expense a...)

Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results

Date:3/28/2008

The selling and administrative expense as a percentage of sales was 26.1% for the twelve months ended December 31, 2007 compared to 19.1% for the same period in 2006, reflecting an increase in salaries and benefits, consulting expenses, insurance costs and depreciation expenses, and the aforementioned decrease in sales.

As of December 31, 2007, Tiens had $114 million of retained earnings and total shareholders' equity of $146 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, "2007 was a year in which Tiens faced challenges from the direct selling environment in China and in exporting its products internationally. To date no problems have been found with our high quality products under the national campaign in China to prevent the export of unsafe food and substandard products. We continued to lay the groundwork for both domestic and international sales growth by acquiring Life Resources, which will provide new research and development facilities and enhance our manufacturing capabilities."

About Tiens Biotech Group (USA), Inc. (http://www.tiens-bio.com)

Tiens Biotech Group (USA), Inc. (AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary nutrition supplement products, and personal care products.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 52 countries. Since its establishment, Tiens has developed and produced 33 nutrition supplements, which include wellness products and dietary supplements.
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
2. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
4. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
5. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
6. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
7. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
8. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
9. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
10. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
11. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia

Post Your Comments:

Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Mon...(The selling and administrative expense a...)